Literature DB >> 16940138

In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti.

Bruno Pradines, Modeste Mabika Mamfoumbi, Adama Tall, Cheikh Sokhna, Jean-Louis Koeck, Thierry Fusai, Joel Mosnier, Eric Czarnecki, André Spiegel, Jean-François Trape, Maryvonne Kombila, Christophe Rogier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940138      PMCID： PMC1563556          DOI： 10.1128/AAC.00777-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  13 in total

1.  A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.

Authors:  G D Shanks; A J Oloo; G M Aleman; C Ohrt; F W Klotz; D Braitman; J Horton; R Brueckner
Journal:  Clin Infect Dis       Date:  2001-11-07       Impact factor: 9.079

2.  Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.

Authors:  Peter Nasveld; Scott Kitchener; Michael Edstein; Karl Rieckmann
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 Nov-Dec       Impact factor: 2.184

3.  Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in thai soldiers receiving monthly prophylaxis.

Authors:  Michael D Edstein; David A Kocisko; Douglas S Walsh; Chirapa Eamsila; Bruce G Charles; Karl H Rieckmann
Journal:  Clin Infect Dis       Date:  2003-11-20       Impact factor: 9.079

4.  First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.

Authors:  R P Brueckner; K C Lasseter; E T Lin; B G Schuster
Journal:  Am J Trop Med Hyg       Date:  1998-05       Impact factor: 2.345

5.  Malaria chemoprophylaxis with tafenoquine: a randomised study.

Authors:  B Lell; J F Faucher; M A Missinou; S Borrmann; O Dangelmaier; J Horton; P G Kremsner
Journal:  Lancet       Date:  2000-06-10       Impact factor: 79.321

6.  In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum.

Authors:  B Pradines; A Tall; F Ramiandrasoa; A Spiegel; C Sokhna; T Fusai; J Mosnier; W Daries; J F Trape; G Kunesch; D Parzy; C Rogier
Journal:  J Antimicrob Chemother       Date:  2006-04-04       Impact factor: 5.790

7.  8-Aminoquinolines active against blood stage Plasmodium falciparum in vitro inhibit hematin polymerization.

Authors:  J L Vennerstrom; E O Nuzum; R E Miller; A Dorn; L Gerena; P A Dande; W Y Ellis; R G Ridley; W K Milhous
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

8.  A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.

Authors:  Braden R Hale; Seth Owusu-Agyei; David J Fryauff; Kwadwo A Koram; Martin Adjuik; Abraham R Oduro; W Roy Prescott; J Kevin Baird; Francis Nkrumah; Thomas L Ritchie; Eileen D Franke; Fred N Binka; John Horton; Stephen L Hoffman
Journal:  Clin Infect Dis       Date:  2003-02-14       Impact factor: 9.079

9.  Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic.

Authors:  Bruce M Russell; Rachanee Udomsangpetch; Karl H Rieckmann; Barbara M Kotecka; Russell E Coleman; Jetsumon Sattabongkot
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  The chemotherapy of rodent malaria. LI. Studies on a new 8-aminoquinoline, WR 238,605.

Authors:  W Peters; B L Robinson; W K Milhous
Journal:  Ann Trop Med Parasitol       Date:  1993-12
View more
  16 in total

1.  Antimalarial activity of the anticancer histone deacetylase inhibitor SB939.

Authors:  Subathdrage D M Sumanadasa; Christopher D Goodman; Andrew J Lucke; Tina Skinner-Adams; Ishani Sahama; Ashraful Haque; Tram Anh Do; Geoffrey I McFadden; David P Fairlie; Katherine T Andrews
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

2.  Methemoglobinemia caused by 8-aminoquinoline drugs: DFT calculations suggest an analogy to H4B's role in nitric oxide synthase.

Authors:  Haining Liu; Larry A Walker; N P Dhammika Nanayakkara; Robert J Doerksen
Journal:  J Am Chem Soc       Date:  2011-01-18       Impact factor: 15.419

3.  Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Authors:  Stephan Meister; David M Plouffe; Kelli L Kuhen; Ghislain M C Bonamy; Tao Wu; S Whitney Barnes; Selina E Bopp; Rachel Borboa; A Taylor Bright; Jianwei Che; Steve Cohen; Neekesh V Dharia; Kerstin Gagaring; Montip Gettayacamin; Perry Gordon; Todd Groessl; Nobutaka Kato; Marcus C S Lee; Case W McNamara; David A Fidock; Advait Nagle; Tae-gyu Nam; Wendy Richmond; Jason Roland; Matthias Rottmann; Bin Zhou; Patrick Froissard; Richard J Glynne; Dominique Mazier; Jetsumon Sattabongkot; Peter G Schultz; Tove Tuntland; John R Walker; Yingyao Zhou; Arnab Chatterjee; Thierry T Diagana; Elizabeth A Winzeler
Journal:  Science       Date:  2011-11-17       Impact factor: 47.728

4.  Malaria in the Republic of Djibouti, 1998-2009.

Authors:  Lénaïck Ollivier; Remington L Nevin; Houssein Y Darar; Jacques Bougère; Moustapha Saleh; Stéphane Gidenne; Jérôme Maslin; Dietmar Anders; Christophe Decam; Alain Todesco; Bouh A Khaireh; Ammar A Ahmed
Journal:  Am J Trop Med Hyg       Date:  2011-09       Impact factor: 2.345

5.  Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.

Authors:  Ann K Miller; Emma Harrell; Li Ye; Sharon Baptiste-Brown; Jőrg-Peter Kleim; Colin Ohrt; Stephan Duparc; Jörg J Möhrle; Alison Webster; Sandra Stinnett; Arlene Hughes; Sandy Griffith; Andrew P Beelen
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

6.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

7.  Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs.

Authors:  Bécaye Fall; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Boubacar Wade; Raymond Bercion; Bruno Pradines
Journal:  Malar J       Date:  2011-10-20       Impact factor: 2.979

8.  Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.

Authors:  Sean R Marcsisin; Jason C Sousa; Gregory A Reichard; Diana Caridha; Qiang Zeng; Norma Roncal; Ronan McNulty; Julio Careagabarja; Richard J Sciotti; Jason W Bennett; Victor E Zottig; Gregory Deye; Qigui Li; Lisa Read; Mark Hickman; N P Dhammika Nanayakkara; Larry A Walker; Bryan Smith; Victor Melendez; Brandon S Pybus
Journal:  Malar J       Date:  2014-01-03       Impact factor: 2.979

9.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

10.  A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.

Authors:  Neils B Quashie; Nancy O Duah; Benjamin Abuaku; Lydia Quaye; Ruth Ayanful-Torgby; George A Akwoviah; Margaret Kweku; Jacob D Johnson; Naomi W Lucchi; Venkatachalam Udhayakumar; Christopher Duplessis; Karl C Kronmann; Kwadwo A Koram
Journal:  Malar J       Date:  2013-12-17       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.